Robert Malone had nearly no involvement with mRNA vaccines. He is not recognized as even a niche contributor by the medical & scientific community. Stop shoveling antivaxer Covid-denier nonsense.
LOL. 15 patents
PATENTS ISSUED:
1. Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response. Assigned to Vical, Inc and licensed to Merck. No. 7,250,404, date of issue: 7/31/07 Cited in 105 articles.
2. Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,867,195 B1, date of issue: 3/15/05.
3. Generation of an immune response to a pathogen. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,710,035, date of issue: 3/23/04. Citations: 37 articles.
4. Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,673,776, date of issue: 1/6/04.
5. Methods of delivering a physiologically active polypeptide to a mammal. Assigned to Vical, Inc,
licensed to Merck. US Pat. Ser. No. 6.413.942, date of issue: 7/2/02. (cited in 150 articles).
6. Induction of a protective immune response in a mammal by injecting a DNA sequence (includes
mRNA). Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,214,804, date of issue:
4/10/01. Cited in 359 articles.
7. DNA vaccines for eliciting a mucosal immune response (includes mRNA). US Pat. Ser. No.
6,110,898, date of issue: 8/29/00. Cited in 40 articles.
8. Formulations and methods for generating active cytofectin: polynucleotide transfection complexes.
US Pat. Ser. No. 5,925,623 7/20/99.
10
Robert W. Malone, MD, MS
9. Cationic Transport Reagents. US Pat. Ser. No. 5,892,071 issued 4/06/99.
10. Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:
polynucleotide transfection complexes. US Pat. Ser. No. 5,824,812 issued 10/20/98.
11. Cationic Transport Reagents. US Pat. Ser. No. 5,744,625 issued 4/28/98.
12. Generation of antibodies through lipid mediated DNA delivery. Assigned to Vical, Inc, licensed to
Merck. US Pat. Ser. No. 5,703,055, date of issue: 12/30/97. Cited in 463 articles.
13. Induction of a protective immune response in a mammal by injecting a DNA sequence (includes
mRNA). Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,589,466, date of issue:
12/31/96. Cited in 889 articles.
14. Delivery of exogenous DNA sequences in a mammal (includes mRNA). Assigned to Vical, Inc,
licensed to Merck. US Pat. Ser. No. 5,580,859, date of issue: 12/3/96. Cited in 1234 articles.
15. Cationic Transport Reagents. US Pat. Ser. No. 5,527,928, date of issue: 6/18/96.